

Temozolomide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
12.0	18.12.2024	27578-00026	03.12.2024
			Date of first issue: 03.11.2014

Section 1: Identification

Product name : Temozolomide Injection Formulation

Manufacturer or supplier's details

Company : MSD

Address : 33 Whakatiki Street - Private Bag 908
Upper Hutt - New Zealand

Telephone : 0800 800 543

Emergency telephone number : 0800 764 766 (0800 POISON) 0800 243 622 (0800 CHEMCALL)

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

Section 2: Hazard identification**GHS Classification**

Serious eye damage/eye irritation : Category 2

Germ cell mutagenicity : Category 2

Carcinogenicity : Category 2

Reproductive toxicity : Category 1

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Bone marrow, thymus gland, Lymph nodes, spleen)

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H319 Causes serious eye irritation.
H341 Suspected of causing genetic defects.
H351 Suspected of causing cancer.

Temozolomide Injection Formulation

Version 12.0	Revision Date: 18.12.2024	SDS Number: 27578-00026	Date of last issue: 03.12.2024 Date of first issue: 03.11.2014
-----------------	------------------------------	----------------------------	---

H360FD May damage fertility. May damage the unborn child.
H373 May cause damage to organs (Bone marrow, thymus gland, Lymph nodes, spleen) through prolonged or repeated exposure if swallowed.

Precautionary statements :

Prevention:
P201 Obtain special instructions before use.
P264 Wash skin thoroughly after handling.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P337 + P313 If eye irritation persists: Get medical advice/ attention.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Citric acid	77-92-9	>= 10 -< 20
Temozolomide	85622-93-1	>= 1 -< 10

Section 4: First-aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.

Temozolomide Injection Formulation

Version 12.0	Revision Date: 18.12.2024	SDS Number: 27578-00026	Date of last issue: 03.12.2024 Date of first issue: 03.11.2014
-----------------	------------------------------	----------------------------	---

- | | |
|---|--|
| | Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention. |
| If swallowed | : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water. |
| Most important symptoms and effects, both acute and delayed | : Contact with dust can cause mechanical irritation or drying of the skin.
Causes serious eye irritation.
Suspected of causing genetic defects.
Suspected of causing cancer.
May damage fertility. May damage the unborn child.
May cause damage to organs through prolonged or repeated exposure if swallowed. |
| Protection of first-aiders | : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| Notes to physician | : Treat symptomatically and supportively. |
-

Section 5: Fire-fighting measures

- | | |
|---|---|
| Suitable extinguishing media | : Water spray
Alcohol-resistant foam
Carbon dioxide (CO ₂)
Dry chemical |
| Unsuitable extinguishing media | : None known. |
| Specific hazards during fire-fighting | : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products | : Carbon oxides
Nitrogen oxides (NO _x)
Metal oxides
Chlorine compounds |
| Specific extinguishing methods | : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area. |
| Special protective equipment for firefighters | : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment. |

Temozolomide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
12.0	18.12.2024	27578-00026	Date of first issue: 03.11.2014

Section 6: Accidental release measures

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Temozolomide Injection Formulation

Version 12.0	Revision Date: 18.12.2024	SDS Number: 27578-00026	Date of last issue: 03.12.2024 Date of first issue: 03.11.2014
-----------------	------------------------------	----------------------------	---

- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

Section 8: Exposure controls/personal protection**Components with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Temozolomide	85622-93-1	TWA	0.1 ug/m3 (OEB 5)	Internal
		Wipe limit	1 µg/100 cm2	Internal

- Engineering measures** : The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.
Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
No open handling permitted.
Totally enclosed processes and materials transport systems are required.
Operations require the use of appropriate containment tech-

Temozolomide Injection Formulation

Version 12.0	Revision Date: 18.12.2024	SDS Number: 27578-00026	Date of last issue: 03.12.2024 Date of first issue: 03.11.2014
-----------------	------------------------------	----------------------------	---

nology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Particulates type
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Section 9: Physical and chemical properties

Appearance	:	powder
Colour	:	white
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available

Temozolomide Injection Formulation

Version 12.0	Revision Date: 18.12.2024	SDS Number: 27578-00026	Date of last issue: 03.12.2024 Date of first issue: 03.11.2014
-----------------	------------------------------	----------------------------	---

Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable
Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	soluble
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics Particle size	:	No data available

Section 10: Stability and reactivity

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

Temozolomide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
12.0	18.12.2024	27578-00026	Date of first issue: 03.11.2014

Section 11: Toxicological information

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

|| Not classified based on available information.

Product:

|| Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:**Citric acid:**

Acute oral toxicity : LD50 (Mouse): 5,400 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Temozolomide:

Acute oral toxicity : LD50 (Dog): 19 mg/kg
LD50 (Rat): 315 mg/kg
LD50 (Mouse): 205 mg/kg

Skin corrosion/irritation

|| Not classified based on available information.

Components:**Citric acid:**

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Serious eye damage/eye irritation

|| Causes serious eye irritation.

Components:**Citric acid:**

Species : Rabbit
Result : Irritation to eyes, reversing within 21 days
Method : OECD Test Guideline 405

Temozolomide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
12.0	18.12.2024	27578-00026	Date of first issue: 03.11.2014

Respiratory or skin sensitisation**Skin sensitisation**

|| Not classified based on available information.

Respiratory sensitisation

|| Not classified based on available information.

Components:**Temozolomide:**

Test Type	:	Maximisation Test
Exposure routes	:	Dermal
Species	:	Guinea pig
Result	:	negative

Chronic toxicity**Germ cell mutagenicity**

|| Suspected of causing genetic defects.

Components:**Citric acid:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
-----------------------	---	--

	:	Test Type: in vitro micronucleus test Result: positive
--	---	---

	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
--	---	--

Genotoxicity in vivo	:	Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Rat Application Route: Ingestion Result: negative
----------------------	---	--

Temozolomide:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: positive
-----------------------	---	--

	:	Test Type: Chromosome aberration test in vitro Test system: Human lymphocytes Result: positive
--	---	--

Germ cell mutagenicity - Assessment	:	Positive results from in vitro mammalian mutagenicity assays, chemical structure activity relationship to known germ cell mutagens
-------------------------------------	---	--

Temozolomide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
12.0	18.12.2024	27578-00026	Date of first issue: 03.11.2014

Carcinogenicity

|| Suspected of causing cancer.

Components:**Temozolomide:**

Species	:	Rat
Application Route	:	Oral
Exposure time	:	6 Months
	:	4 mg/kg body weight
Result	:	positive
Target Organs	:	Mammary gland

Carcinogenicity - Assessment	:	Limited evidence of carcinogenicity in animal studies
------------------------------	---	---

Reproductive toxicity

|| May damage fertility. May damage the unborn child.

Components:**Citric acid:**

Effects on foetal development	:	Test Type: One-generation reproduction toxicity study
		Species: Rat
		Application Route: Ingestion
		Result: negative

Temozolomide:

Effects on fertility	:	Test Type: Fertility/early embryonic development
		Species: Rat, male
		Application Route: Oral
		Fertility: LOAEL: 8.5 mg/kg body weight
		Result: positive

Effects on foetal development	:	Test Type: Embryo-foetal development
		Species: Rat
		Application Route: Oral
		Embryo-foetal toxicity: LOAEL: 13 mg/kg body weight
		Result: positive, Malformations were observed.

Reproductive toxicity - Assessment	:	Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.
------------------------------------	---	--

STOT - single exposure

|| Not classified based on available information.

Components:**Citric acid:**

Assessment	:	May cause respiratory irritation.
------------	---	-----------------------------------

Temozolomide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
12.0	18.12.2024	27578-00026	Date of first issue: 03.11.2014

STOT - repeated exposure

|| May cause damage to organs (Bone marrow, thymus gland, Lymph nodes, spleen) through prolonged or repeated exposure if swallowed.

Components:**Temozolomide:**

Exposure routes	: Ingestion
Target Organs	: Bone marrow, thymus gland, Lymph nodes, spleen
Assessment	: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Citric acid:**

Species	: Rat
NOAEL	: 4,000 mg/kg
LOAEL	: 8,000 mg/kg
Application Route	: Ingestion
Exposure time	: 10 Days

Temozolomide:

Species	: Rat, female
NOAEL	: 4 mg/kg
LOAEL	: 21 mg/kg
Application Route	: Oral
Exposure time	: 6 Months
Target Organs	: thymus gland, Bone marrow, Reproductive organs, Lymph nodes

Species	: Rat, male
NOAEL	: 8.5 mg/kg
LOAEL	: 34 mg/kg
Application Route	: Oral
Exposure time	: 6 Months
Target Organs	: thymus gland, Bone marrow, male reproductive organs, Gastrointestinal tract, Lymph nodes

Species	: Dog
NOAEL	: 2.5 mg/kg
LOAEL	: 6.3 mg/kg
Application Route	: Oral
Exposure time	: 6 Months
Target Organs	: Bone marrow, spleen, male reproductive organs, Gastrointestinal tract, thymus gland

Aspiration toxicity

|| Not classified based on available information.

Temozolomide Injection Formulation

Version 12.0	Revision Date: 18.12.2024	SDS Number: 27578-00026	Date of last issue: 03.12.2024 Date of first issue: 03.11.2014
-----------------	------------------------------	----------------------------	---

Experience with human exposure**Components:****Temozolomide:**

Ingestion : Symptoms: Blood disorders, Nausea, Vomiting, Diarrhoea, anorexia, Fatigue, hair loss

Section 12: Ecological information**Ecotoxicity****Components:****Citric acid:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,535 mg/l
Exposure time: 24 h

Temozolomide:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 90 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 40 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50: > 100 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Persistence and degradability**Components:****Citric acid:**

Biodegradability : Result: Readily biodegradable.

Temozolomide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
12.0	18.12.2024	27578-00026	Date of first issue: 03.11.2014

Biodegradation: 97 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Temozolomide:

Biodegradability : Result: rapidly degradable
Biodegradation: 83 %
Exposure time: 35 d

Stability in water : Degradation half life (DT50): < 1 d

Bioaccumulative potential**Components:****Citric acid:**

Partition coefficient: n-octanol/water : log Pow: -1.72

Temozolomide:

Partition coefficient: n-octanol/water : log Pow: 1.35

Mobility in soil

No data available

Other adverse effects

No data available

Section 13: Disposal considerations**Disposal methods**

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information**International Regulations****UNRTDG**

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Environmentally hazardous : no

IATA-DGR

Temozolomide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
12.0	18.12.2024	27578-00026	Date of first issue: 03.11.2014

UN/ID No.	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
Packing instruction (cargo aircraft)	: Not applicable
Packing instruction (passenger aircraft)	: Not applicable

IMDG-Code

UN number	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
EmS Code	: Not applicable
Marine pollutant	: Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**NZS 5433**

UN number	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
Hazchem Code	: Not applicable

Special precautions for user

Not applicable

Section 15: Regulatory information**Safety, health and environmental regulations/legislation specific for the substance or mixture****HSNO Approval Number**

HSR100425 Pharmaceutical Active Ingredients Group Standard

Tolerable Exposure Limits (TEL)

Not applicable

Environmental Exposure Limits (EEL)

Not applicable

Temozolomide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
12.0	18.12.2024	27578-00026	Date of first issue: 03.11.2014

HSW Controls

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

Section 16: Other information

Revision Date : 18.12.2024

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances

Temozolomide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
12.0	18.12.2024	27578-00026	Date of first issue: 03.11.2014

es; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN